Latest News for: braf

Edit

European Commission Approves Erbitux® (cetuximab) in Combination with Encorafenib and FOLFOX for First-Line Treatment of Metastatic Colorectal Cancer with BRAF V600E Mutation (Merck KGaA)

Public Technologies 14 Jul 2026
Erbitux is now indicated in combination with encorafenib for patients with BRAF V600E-mutant ... "BRAF V600E-mutant mCRC is associated with a historically poor prognosis and limited effective options.
  • 1

Article Search

tools
×
×
×
×